Efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure: A systematic review and meta-analysis.

IF 1.3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Qiushan Man, Shijian Chen, Xingyu Li
{"title":"Efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure: A systematic review and meta-analysis.","authors":"Qiushan Man, Shijian Chen, Xingyu Li","doi":"10.1097/MD.0000000000039927","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Qishen Yiqi dropping pills combined with modern medicine have been widely used as a treatment for coronary heart disease with ischemic heart failure. Currently, there have been no robust studies addressing the efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure. Therefore, this systematic review and meta-analysis are conducted to fill in the gaps mentioned above.</p><p><strong>Methods: </strong>This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies published from inception to April 17, 2023, in the 5 electronic databases: PubMed, The Cochrane Library, EMBASE, CNKI, and the Wanfang database were comprehensively searched. Weighted mean difference was used as the effect size for the continuous variables. Pooled odd ratios are presented if the results are binary variables. Additionally, we performed subgroup and sensitivity analyses to examine the source of heterogeneity. The funnel plot and the Egger test were used to estimate publication bias.</p><p><strong>Results: </strong>This meta-analysis included 46 studies involving 5843 participants. There is a significant difference in clinical efficacy, the 6-minute walk test (weighted mean difference = 50.10; 95% CI 28.19 to 72.02; I2 = 98.9%, P = .000), the indexes of ultrasonic cardiogram, blood biochemical indexes, and adverse effects (odds ratios = 0.46; 95% CI 0.29 to 0.75; I2 = 35.9%, P = .142). The sensitivity analysis and publication bias have demonstrated the robustness of the results (P = .702).</p><p><strong>Conclusion: </strong>Qishen Yiqi dropping pills combined with modern medicine could significantly improve clinical efficacy without incasement adverse effects. Further studies are required to identify the more comprise efficacy and safety results.</p>","PeriodicalId":18549,"journal":{"name":"Medicine","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537573/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000039927","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Qishen Yiqi dropping pills combined with modern medicine have been widely used as a treatment for coronary heart disease with ischemic heart failure. Currently, there have been no robust studies addressing the efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure. Therefore, this systematic review and meta-analysis are conducted to fill in the gaps mentioned above.

Methods: This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies published from inception to April 17, 2023, in the 5 electronic databases: PubMed, The Cochrane Library, EMBASE, CNKI, and the Wanfang database were comprehensively searched. Weighted mean difference was used as the effect size for the continuous variables. Pooled odd ratios are presented if the results are binary variables. Additionally, we performed subgroup and sensitivity analyses to examine the source of heterogeneity. The funnel plot and the Egger test were used to estimate publication bias.

Results: This meta-analysis included 46 studies involving 5843 participants. There is a significant difference in clinical efficacy, the 6-minute walk test (weighted mean difference = 50.10; 95% CI 28.19 to 72.02; I2 = 98.9%, P = .000), the indexes of ultrasonic cardiogram, blood biochemical indexes, and adverse effects (odds ratios = 0.46; 95% CI 0.29 to 0.75; I2 = 35.9%, P = .142). The sensitivity analysis and publication bias have demonstrated the robustness of the results (P = .702).

Conclusion: Qishen Yiqi dropping pills combined with modern medicine could significantly improve clinical efficacy without incasement adverse effects. Further studies are required to identify the more comprise efficacy and safety results.

芪参益气滴丸联合现代药物治疗冠心病合并缺血性心力衰竭的有效性和安全性:系统回顾和荟萃分析。
背景:芪参益气滴丸联合现代药物已被广泛用于冠心病合并缺血性心力衰竭的治疗。目前,还没有针对芪参益气滴丸联合现代药物治疗冠心病合并缺血性心力衰竭的疗效和安全性的可靠研究。因此,本系统综述和荟萃分析旨在填补上述空白:本系统综述按照《系统综述和荟萃分析首选报告项目》指南进行研究和报告。从开始到 2023 年 4 月 17 日在 5 个电子数据库中发表的相关研究:全面检索了 PubMed、The Cochrane Library、EMBASE、CNKI 和万方数据库。连续变量采用加权平均差作为效应大小。如果结果是二元变量,则采用汇总奇数比。此外,我们还进行了亚组分析和敏感性分析,以研究异质性的来源。漏斗图和 Egger 检验用于估计发表偏倚:这项荟萃分析包括 46 项研究,涉及 5843 名参与者。在临床疗效、6 分钟步行测试(加权平均差 = 50.10;95% CI 28.19 至 72.02;I2 = 98.9%,P = .000)、超声心动图指标、血液生化指标和不良反应(几率比 = 0.46;95% CI 0.29 至 0.75;I2 = 35.9%,P = .142)方面存在明显差异。敏感性分析和发表偏倚证明了结果的稳健性(P = .702):结论:芪参益气滴丸与现代医学相结合可显著提高临床疗效,且不会增加不良反应。结论:芪参益气滴丸与现代药物结合可明显提高临床疗效,且不会增加不良反应,但还需进一步研究以确定更全面的疗效和安全性结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicine
Medicine 医学-医学:内科
CiteScore
2.80
自引率
0.00%
发文量
4342
审稿时长
>12 weeks
期刊介绍: Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信